OmniAb, Inc. (OABI)

Acerca de OmniAb, Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Al 3 de noviembre de 2026, la acción de OmniAb, Inc. (OABI) avanzó ligeramente a $5.10, un alza de 0.20% (+$0.01) frente al cierre anterior. En la sesión, las acciones han operado entre $5.02 y $5.37. Eso ubica a OABI cerca del máximo de su rango de 52 semanas, de $1.30 a $5.43. OmniAb, Inc. opera en el sector de services-commercial physical & biological research y tiene una capitalización de mercado de aproximadamente $742.43 millones, con cerca de 950.7 mil acciones negociadas.

Últimas noticias de OABI

• OmniAb (OABI) Q3 Results Keep Cash Progress In FocusYahoo Finance· 1 nov, 4:11 a.m. ET
• OmniAb, Inc. Q3 2026 Earnings Call Summaryapp.moby.co· 30 oct, 5:03 p.m. ET
• OmniAb (OABI) Q3 2026 Earnings Call Transcriptfool.com· 30 oct, 2:58 p.m. ET
• OmniAb Q3 Earnings Call Highlightsmarketbeat.com· 30 oct, 11:14 a.m. ET
• OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance· 30 oct, 7:50 a.m. ET
• OmniAb Reports Third Quarter 2026 Financial Results and Business HighlightsYahoo Finance· 30 oct, 7:40 a.m. ET
• OmniAb to Participate in Upcoming Investor Conferences in NovemberYahoo Finance· 26 oct, 4:05 p.m. ET
• OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conferencemarketbeat.com· 25 oct, 12:02 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de OABI en un solo lugar? Crea una cuenta gratis →

• $OABI As OABI grows into more of a royalty driven company earnings should really take off. Silly why so many sold after the earnings call Nice recovery at the close Lots of potential here

  @bearsoil· 30 oct, 7:38 p.m. ET

• $OABI Not a bad close ! Not bad

  @Posna· 30 oct, 3:48 p.m. ET

• $OABI reported before the open this morning. GAAP EPS of -$0.12 beat the -$0.13 analyst estimate by 5.6%, according to Stock Meadow. Revenue was $3.99M versus $3.49M expected.

  @shoc24· 30 oct, 2:15 p.m. ET· Alcista

• https://www.marketbeat.com/earnings/reports/2026-10-30-omniab-inc-stock/ $OABI OmniAb Earnings Transcript

  @EarningsInsider· 30 oct, 9:01 a.m. ET

• $OABI its fate is completely tied to success or failure of its partners. It will probably not dilute for another 6 months or so. If JNJ-79635322 gives it a milestone payment in the meantime, it may not need to dilute at all. The organic company revenues are tiny and irrelevant…

  @HypnoTrader· 30 oct, 8:51 a.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →